These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 33341987)

  • 1. Poly(ADP-ribose) polymerase inhibition in pancreatic cancer.
    Singh HM; Bailey P; Hübschmann D; Berger AK; Neoptolemos JP; Jäger D; Siveke J; Springfeld C
    Genes Chromosomes Cancer; 2021 May; 60(5):373-384. PubMed ID: 33341987
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of PARP inhibitors in germline BRCA-associated pancreatic ductal adenocarcinoma.
    Moffat GT; O'Reilly EM
    Clin Adv Hematol Oncol; 2020 Mar; 18(3):168-179. PubMed ID: 32609666
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PARP inhibition in treatment of pancreatic cancer.
    Hammel P; Zhang C; Matile J; Colle E; Hadj-Naceur I; Gagaille MP; Bouattour M; Cros J; de Mestier L; Lamuraglia M
    Expert Rev Anticancer Ther; 2020 Nov; 20(11):939-945. PubMed ID: 32936674
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Maintenance Therapy for ATM-Deficient Pancreatic Cancer by Multiple DNA Damage Response Interferences after Platinum-Based Chemotherapy.
    Roger E; Gout J; Arnold F; Beutel AK; Müller M; Abaei A; Barth TFE; Rasche V; Seufferlein T; Perkhofer L; Kleger A
    Cells; 2020 Sep; 9(9):. PubMed ID: 32948057
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting DNA damage repair pathways in pancreas cancer.
    Crowley F; Park W; O'Reilly EM
    Cancer Metastasis Rev; 2021 Sep; 40(3):891-908. PubMed ID: 34403012
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emerging strategies in BRCA-positive pancreatic cancer.
    Kowalewski A; Szylberg Ł; Saganek M; Napiontek W; Antosik P; Grzanka D
    J Cancer Res Clin Oncol; 2018 Aug; 144(8):1503-1507. PubMed ID: 29777302
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Beyond BRCA: Diagnosis and management of homologous recombination repair deficient pancreatic cancer.
    LaRose M; Manji GA; Bates SE
    Semin Oncol; 2024; 51(1-2):36-44. PubMed ID: 38171988
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The BET inhibitor JQ1 attenuates double-strand break repair and sensitizes models of pancreatic ductal adenocarcinoma to PARP inhibitors.
    Miller AL; Fehling SC; Garcia PL; Gamblin TL; Council LN; van Waardenburg RCAM; Yang ES; Bradner JE; Yoon KJ
    EBioMedicine; 2019 Jun; 44():419-430. PubMed ID: 31126889
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pancreas cancer and BRCA: A critical subset of patients with improving therapeutic outcomes.
    Momtaz P; O'Connor CA; Chou JF; Capanu M; Park W; Bandlamudi C; Berger MF; Kelsen DP; Suehnholz SP; Chakravarty D; Yu KH; Varghese AM; Zervoudakis A; Li J; Ku GY; Park JS; Shcherba M; Harding JJ; Goldberg Z; Abou-Alfa GK; Salo-Mullen EE; Stadler ZK; Iacobuzio-Donahue CA; O'Reilly EM
    Cancer; 2021 Dec; 127(23):4393-4402. PubMed ID: 34351646
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recapitulating the clinical scenario of BRCA-associated pancreatic cancer in pre-clinical models.
    Golan T; Stossel C; Atias D; Buzhor E; Halperin S; Cohen K; Raitses-Gurevich M; Glick Y; Raskin S; Yehuda D; Feldman A; Schvimer M; Friedman E; Karni R; Wilson JM; Denroche RE; Lungu I; Bartlett JMS; Mbabaali F; Gallinger S; Berger R
    Int J Cancer; 2018 Jul; 143(1):179-183. PubMed ID: 29396858
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [New drug approval: Olaparib - pancreatic cancer with BRCA germline mutation].
    Hilmi M; Neuzillet C
    Bull Cancer; 2020 Oct; 107(10):961-962. PubMed ID: 32943226
    [No Abstract]   [Full Text] [Related]  

  • 12. BRCA2 secondary mutation-mediated resistance to platinum and PARP inhibitor-based therapy in pancreatic cancer.
    Pishvaian MJ; Biankin AV; Bailey P; Chang DK; Laheru D; Wolfgang CL; Brody JR
    Br J Cancer; 2017 Apr; 116(8):1021-1026. PubMed ID: 28291774
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genomic profiling in pancreatic ductal adenocarcinoma and a pathway towards therapy individualization: A scoping review.
    Singh RR; Goldberg J; Varghese AM; Yu KH; Park W; O'Reilly EM
    Cancer Treat Rev; 2019 May; 75():27-38. PubMed ID: 30927677
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Abnormalities of DNA repair and gynecological cancers].
    Auguste A; Leary A
    Bull Cancer; 2017 Nov; 104(11):971-980. PubMed ID: 29054544
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PARPis and Other Novel, Targeted Therapeutics in Pancreatic Adenocarcinoma.
    Chapin WJ; Reiss KA
    Hematol Oncol Clin North Am; 2022 Oct; 36(5):1019-1032. PubMed ID: 36154785
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II trial of veliparib in patients with previously treated BRCA-mutated pancreas ductal adenocarcinoma.
    Lowery MA; Kelsen DP; Capanu M; Smith SC; Lee JW; Stadler ZK; Moore MJ; Kindler HL; Golan T; Segal A; Maynard H; Hollywood E; Moynahan M; Salo-Mullen EE; Do RKG; Chen AP; Yu KH; Tang LH; O'Reilly EM
    Eur J Cancer; 2018 Jan; 89():19-26. PubMed ID: 29223478
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dynamic immunoediting by macrophages in homologous recombination deficiency-stratified pancreatic ductal adenocarcinoma.
    Hong WF; Zhang F; Wang N; Bi JM; Zhang DW; Wei LS; Song ZT; Mills GB; Chen MM; Li XX; Du SS; Yu M
    Drug Resist Updat; 2024 Sep; 76():101115. PubMed ID: 39002266
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emerging therapeutic modalities of PARP inhibitors in breast cancer.
    Wang X; Shi Y; Huang D; Guan X
    Cancer Treat Rev; 2018 Jul; 68():62-68. PubMed ID: 29870916
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rapid Progression of Metastatic Pancreatic Adenocarcinoma During Platinum-Based Therapy in a Patient Harboring a Pathogenic BRCA2 Germline Variant.
    Sorscher S; Ramkissoon S
    Oncologist; 2021 Nov; 26(11):916-918. PubMed ID: 34309133
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Spectrum of Response to Platinum and PARP Inhibitors in Germline BRCA-Associated Pancreatic Cancer in the Clinical and Preclinical Setting.
    Stossel C; Raitses-Gurevich M; Atias D; Beller T; Glick Gorman Y; Halperin S; Peer E; Denroche RE; Zhang A; Notta F; Wilson JM; O'Kane GM; Haimov Talmoud E; Amison N; Schvimer M; Salpeter SJ; Bar V; Zundelevich A; Tirosh I; Tal R; Dinstag G; Kinar Y; Eliezer Y; Ben-David U; Gavert NS; Straussman R; Gallinger SJ; Berger R; Golan T
    Cancer Discov; 2023 Aug; 13(8):1826-1843. PubMed ID: 37449843
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.